Deodhar A, van der Heijde D, Gensler LS, et al. - Researchers conducted a study, COAST-X was a 52-week, randomized, double-blind, placebo-controlled, parallel-group at 107 sites in 15 countries in Europe, Asia, North America, and South America in order to assess the effectiveness and safety of ixekizumab, an IL-17 inhibitor, in non-radiographic axial spondyloarthritis. Selected participants were adults with active axial spondyloarthritis without definite radiographic sacroiliitis, objective signs of inflammation, and an incomplete response or not tolerated to NSAIDs. People were randomly selected (1:1:1) to obtain subcutaneous 80 mg ixekizumab every 4 weeks or every 2 weeks, or placebo. It was found that Ixekizumab was superior to placebo for improving signs and symptoms in individuals with non-radiographic axial spondyloarthritis at weeks 16 and 52. Reports of adverse events were alike to those of previous ixekizumab studies. Moreover, ixekizumab gives a possible therapeutic choice for people with non-radiographic axial spondyloarthritis who had an unsatisfactory response or were not tolerated to NSAID therapy.